11 research outputs found
Key issues in the persistence of poliomyelitis in Nigeria: a case-control study
Background The completion of poliomyelitis eradication is a global emergency for public health. In 2012, more than
50% of the worldâs cases occurred in Nigeria following an unanticipated surge in incidence. We aimed to quantitatively
analyse the key factors sustaining transmission of poliomyelitis in Nigeria and to calculate clinical effi cacy estimates
for the oral poliovirus vaccines (OPV) currently in use.
Methods We used acute fl accid paralysis (AFP) surveillance data from Nigeria collected between January, 2001, and
December, 2012, to estimate the clinical effi cacies of all four OPVs in use and combined this with vaccination coverage
to estimate the eff ect of the introduction of monovalent and bivalent OPV on vaccine-induced serotype-specifi c
population immunity. Vaccine effi cacy was determined using a case-control study with CIs based on bootstrap
resampling. Vaccine effi cacy was also estimated separately for north and south Nigeria, by age of the children, and by
year. Detailed 60-day follow-up data were collected from children with confi rmed poliomyelitis and were used to
assess correlates of vaccine status. We also quantitatively assessed the epidemiology of poliomyelitis and programme
performance and considered the reasons for the high vaccine refusal rate along with risk factors for a given local
government area reporting a case.
Findings Against serotype 1, both monovalent OPV (median 32¡1%, 95% CI 26¡1â38¡1) and bivalent OPV (29¡5%,
20¡1â38¡4) had higher clinical effi cacy than trivalent OPV (19¡4%, 16¡1â22¡8). Corresponding data for serotype 3 were
43¡2% (23¡1â61¡1) and 23¡8% (5¡3â44¡9) compared with 18¡0% (14¡1â22¡1). Combined with increases in coverage,
this factor has boosted population immunity in children younger than age 36 months to a record high (64â69%
against serotypes 1 and 3). Vaccine effi cacy in northern states was estimated to be signifi cantly lower than in southern
states (pâ¤0¡05). The proportion of cases refusing vaccination decreased from 37â72% in 2008 to 21â51% in 2012 for
routine and supplementary immunisation, and most caregivers cited ignorance of either vaccine importance or
availability as the main reason for missing routine vaccinations (32¡1% and 29¡6% of cases, respectively). Multiple
regression analyses highlighted associations between the age of the mother, availability of OPV at health facilities,
and the primary source of health information and the probability of receiving OPV (all p<0¡05).
Interpretation Although high refusal rates, low OPV campaign awareness, and heterogeneous population immunity
continued to support poliomyelitis transmission in Nigeria at the end of 2012, overall population immunity had
improved due to new OPV formulations and improvements in programme delivery.Funding Bill & Melinda Gates Foundation Vaccine Modeling Initiative, Royal Society.Introduction In May, 2012, after more than 20 years of mass vaccination campaigns, the 65t
Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population
Wild poliovirus has remained endemic in northern Nigeria because of low coverage achieved in the routine immunization program and in supplementary immunization activities (SIAs). An outbreak of infection involving 315 cases of type 2 circulating vaccine-derived poliovirus (cVDPV2; >1% divergent from Sabin 2) occurred during July 2005âJune 2010, a period when 23 of 34 SIAs used monovalent or bivalent oral poliovirus vaccine (OPV) lacking Sabin 2. In addition, 21 âpre-VDPV2â (0.5%â1.0% divergent) cases occurred during this period. Both cVDPV and pre-VDPV cases were clinically indistinguishable from cases due to wild poliovirus. The monthly incidence of cases increased sharply in early 2009, as more children aged without trivalent OPV SIAs. Cumulative state incidence of pre-VDPV2/cVDPV2 was correlated with low childhood immunization against poliovirus type 2 assessed by various means. Strengthened routine immunization programs in countries with suboptimal coverage and balanced use of OPV formulations in SIAs are necessary to minimize risks of VDPV emergence and circulation
Simulated population movement under the radiation model from Kano Municipal Area, Kano state (population density 14 064.1 people per km<sup>2</sup>).
<p>Population movements with fewer than ten people are excluded.</p
Univariate Analysis of Potential Explanatory Variables Associated With Risk of Poliomyelitis Cases in Nigeria, 2001â2013 Using a Poisson Mixed Effects Regression Model.
<p>Univariate Analysis of Potential Explanatory Variables Associated With Risk of Poliomyelitis Cases in Nigeria, 2001â2013 Using a Poisson Mixed Effects Regression Model.</p
The expected number of LGAs (of 774) reporting at least one case of poliomyelitis during each six month period.
<p>The shaded area represents 95% of the distribution of outcomes using 1000 simulations of the radiation model with the actual number of LGAs reporting a case overlaid in blue.</p
Optimised Estimates for Components of the Spatial and Non-Spatial Models and the Poisson Mixed-Effects Model Coefficients.
<p>Optimised Estimates for Components of the Spatial and Non-Spatial Models and the Poisson Mixed-Effects Model Coefficients.</p
Key issues in the persistence of poliomyelitis in Nigeria: a case-control study
Background: The completion of poliomyelitis eradication is a global emergency for public health. In 2012, more than 50% of the world's cases occurred in Nigeria following an unanticipated surge in incidence. We aimed to quantitatively analyse the key factors sustaining transmission of poliomyelitis in Nigeria and to calculate clinical efficacy estimates for the oral poliovirus vaccines (OPV) currently in use.
Methods: We used acute flaccid paralysis (AFP) surveillance data from Nigeria collected between January, 2001, and December, 2012, to estimate the clinical efficacies of all four OPVs in use and combined this with vaccination coverage to estimate the effect of the introduction of monovalent and bivalent OPV on vaccine-induced serotype-specific population immunity. Vaccine efficacy was determined using a case-control study with CIs based on bootstrap resampling. Vaccine efficacy was also estimated separately for north and south Nigeria, by age of the children, and by year. Detailed 60-day follow-up data were collected from children with confirmed poliomyelitis and were used to assess correlates of vaccine status. We also quantitatively assessed the epidemiology of poliomyelitis and programme performance and considered the reasons for the high vaccine refusal rate along with risk factors for a given local government area reporting a case.
Findings: Against serotype 1, both monovalent OPV (median 32¡1%, 95% CI 26¡1â38¡1) and bivalent OPV (29¡5%, 20¡1â38¡4) had higher clinical efficacy than trivalent OPV (19¡4%, 16¡1â22¡8). Corresponding data for serotype 3 were 43¡2% (23¡1â61¡1) and 23¡8% (5¡3â44¡9) compared with 18¡0% (14¡1â22¡1). Combined with increases in coverage, this factor has boosted population immunity in children younger than age 36 months to a record high (64â69% against serotypes 1 and 3). Vaccine efficacy in northern states was estimated to be significantly lower than in southern states (pâ¤0¡05). The proportion of cases refusing vaccination decreased from 37â72% in 2008 to 21â51% in 2012 for routine and supplementary immunisation, and most caregivers cited ignorance of either vaccine importance or availability as the main reason for missing routine vaccinations (32¡1% and 29¡6% of cases, respectively). Multiple regression analyses highlighted associations between the age of the mother, availability of OPV at health facilities, and the primary source of health information and the probability of receiving OPV (all p<0¡05).
Interpretation: Although high refusal rates, low OPV campaign awareness, and heterogeneous population immunity continued to support poliomyelitis transmission in Nigeria at the end of 2012, overall population immunity had improved due to new OPV formulations and improvements in programme delivery.
Funding: Bill & Melinda Gates Foundation Vaccine Modeling Initiative, Royal Society